The integrated capabilities at Unit 2 offer significant operational flexibility, greater efficiency, and varied scope within the same premise
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Dr. Pedrocchi is currently an Independent Strategic Advisor and Non-Executive Director to private and public healthcare companies.
Subject Expert Committee(SEC) of Central Drugs Standard Control Organization (CDSCO)
The Centre aims at promoting innovation among the scientific community to improve healthcare solutions around the globe
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
Post-acquisition, Cipla EU's stake in the subsidiary will increase to 93.10%.
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)
The MOU provides for assistance in the form of efficient working Capital Management, development and commercialisation of new products, logistic supply chain management support etc.
Subscribe To Our Newsletter & Stay Updated
